News Detail
New Delhi, 16 May 2024: The Division Bench of Delhi High Court, which is hearing the petitions by pharmaceutical manufacturers against the Central government’s order prohibiting 14 fixed dose combinations (FDCs), has directed the petitioner firms and organisations to file a......
View Details
Source : Pharmabiz
Division Bench
Delhi High Court
Central government
fixed dose combinations
FDCs
Acting Chief Justice Manmohan
Lupin
Gazette of India
DTAB
Section 26A
Drugs and Cosmetics Act
Dr Reddy’s Laboratories
Abbott Healthcare
Cipla
Lupin
Alkem Laboratories
Mankind Pharma
Intas Pharmaceuticals
Seagull Laboratories
Laborate Pharmaceuticals
Laboratories Griffon
Shreya Life Sciences
Obsurge
Leeford Healthcare
CCI Products
JD Pharma
Related News
- Two Individuals Arrested with 2,450 Intoxicating Tablets; FIR Filed (17-03-2025)
- MIT engineers turn skin cells directly into neurons for cell therapy (17-03-2025)
- Police bust illegal sale of expired govt drugs in Kampala, 10 arrested (17-03-2025)
- Sun and Zydus Pharma pulling back some medications in the US due to quality issues (17-03-2025)
- Two Smugglers arrested with 11,520 Illegal Tablets (17-03-2025)
- Huge Stock of illegal cough syrups confiscated, two arrested (17-03-2025)
- Par panel suggests single independent drug controller for AYUSH (17-03-2025)
- Rise in pediatric pneumonia cases underscores the increasing issue of antibiotic resistance (16-03-2025)
- Extended use of steroids linked to risk of glaucoma, AIIMS docs caution (16-03-2025)
- Indian pharma increasing acquisitions in US amid regulatory and market shifts (16-03-2025)